Recent data from a pre-specified analysis of the SELECT trial show a beneficial effect of the glucagon-like peptide-1 receptor agonist (GLP1RA) semaglutide on kidney outcomes in patients with cardiovascular disease and overweight or obesity without diabetes. These findings were presented at the 61st European Renal Association Congress in Stockholm.

The SELECT trial, which included 17,604 participants with cardiovascular disease and BMI ≥27 kg/m² without diabetes, showed that once-weekly treatment with subcutaneous semaglutide (2.4 mg) was associated with a 20% reduction in major cardiovascular events compared with placebo.

SELECT 试验预先指定分析的最新数据显示，胰高血糖素样肽 1 受体激动剂 (GLP1RA) 索马鲁肽对患有心血管疾病且超重或肥胖但不患有糖尿病的患者的肾脏结局具有有益作用。这些发现在斯德哥尔摩举行的第 61 届欧洲肾脏协会大会上公布。

SELECT 试验纳入了 17,604 名患有心血管疾病且 BMI ≥ 27 kg/m ²无糖尿病的参与者，结果表明，与安慰剂相比，每周一次皮下注射索马鲁肽（2.4 mg）治疗可将主要心血管事件减少 20%。